Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

139 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Health-related quality of life effects of enzalutamide in patients with metastatic castration-resistant prostate cancer: an in-depth post hoc analysis of EQ-5D data from the PREVAIL trial.
Devlin N, Herdman M, Pavesi M, Phung D, Naidoo S, Beer TM, Tombal B, Loriot Y, Ivanescu C, Parli T, Balk M, Holmstrom S. Devlin N, et al. Among authors: holmstrom s. Health Qual Life Outcomes. 2017 Jun 23;15(1):130. doi: 10.1186/s12955-017-0704-y. Health Qual Life Outcomes. 2017. PMID: 28645287 Free PMC article. Clinical Trial.
The association between health-related quality-of-life scores and clinical outcomes in metastatic castration-resistant prostate cancer patients: Exploratory analyses of AFFIRM and PREVAIL studies.
Beer TM, Miller K, Tombal B, Cella D, Phung D, Holmstrom S, Ivanescu C, Skaltsa K, Naidoo S. Beer TM, et al. Among authors: holmstrom s. Eur J Cancer. 2017 Dec;87:21-29. doi: 10.1016/j.ejca.2017.09.035. Epub 2017 Oct 31. Eur J Cancer. 2017. PMID: 29096157 Clinical Trial.
Skeletal-related events significantly impact health-related quality of life in metastatic castration-resistant prostate cancer: data from PREVAIL and AFFIRM trials.
Saad F, Ivanescu C, Phung D, Loriot Y, Abhyankar S, Beer TM, Tombal B, Holmstrom S. Saad F, et al. Among authors: holmstrom s. Prostate Cancer Prostatic Dis. 2017 Mar;20(1):110-116. doi: 10.1038/pcan.2016.62. Epub 2017 Jan 3. Prostate Cancer Prostatic Dis. 2017. PMID: 28045115 Free PMC article.
Effect of enzalutamide on health-related quality of life, pain, and skeletal-related events in asymptomatic and minimally symptomatic, chemotherapy-naive patients with metastatic castration-resistant prostate cancer (PREVAIL): results from a randomised, phase 3 trial.
Loriot Y, Miller K, Sternberg CN, Fizazi K, De Bono JS, Chowdhury S, Higano CS, Noonberg S, Holmstrom S, Mansbach H, Perabo FG, Phung D, Ivanescu C, Skaltsa K, Beer TM, Tombal B. Loriot Y, et al. Among authors: holmstrom s. Lancet Oncol. 2015 May;16(5):509-21. doi: 10.1016/S1470-2045(15)70113-0. Epub 2015 Apr 14. Lancet Oncol. 2015. PMID: 25888263 Clinical Trial.
139 results